oncology 
PharmaVoice
MAY 8, 2024
oncology. Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S.
STAT
MAY 2, 2024
BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it concentrates its resources on an anticipated launch of its pivotal heart drug. The subsidiary, a company called TheRAS that is developing treatments for cancers with mutations in the KRAS gene, will become BridgeBio Oncology Therapeutics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MARCH 20, 2024
Robert Ross had thought he would take more time off after his previous company, Surface Oncology, was acquired in September. The immuno-oncology firm had just managed to weather the stormy public markets, which had battered its valuation.
Express Pharma
MARCH 6, 2024
Despite this approval, the CRISPR landscape is dominated by oncology, which accounts for 30 per cent of all active CRISPR drugs. The precision of CRISPR technology makes it an appealing option for oncology therapeutics, presenting a revolutionary approach to cancer treatment, says GlobalData.
STAT
OCTOBER 10, 2022
is about to have not just one, but two, standalone publicly-traded oncology providers. Florida-based American Oncology Network, a company with more than 100 affiliated doctors across 18 states, announced last week it plans to go public. The news comes about a year after another large oncology provider chain hit the stock market.
PharmaVoice
NOVEMBER 2, 2023
From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.
PharmaVoice
AUGUST 17, 2023
The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.
Expert insights. Personalized for you.
240 
Let's personalize your content